tiprankstipranks
Molecular Partners AG (CH:MOLN)
:MOLN
Switzerland Market
MOLN
Molecular Partners AG
RESEARCH TOOLSreports
Want to see CH:MOLN full AI Analyst Report?

Molecular Partners AG (MOLN) Stock News & Sentiment

0 Followers
Molecular Partners: Buy Rating Reaffirmed on Pipeline Progress and Cash Runway, $12 Price Target Unchanged
Premium
Ratings
Molecular Partners: Buy Rating Reaffirmed on Pipeline Progress and Cash Runway, $12 Price Target Unchanged
9d ago
MOLN
Molecular Partners: Unmodeled Upside from MP0632 AND-Gate T Cell Engager Supports Buy Rating and $13 Target
Premium
Ratings
Molecular Partners: Unmodeled Upside from MP0632 AND-Gate T Cell Engager Supports Buy Rating and $13 Target
29d ago
MOLN
Molecular Partners: Strong Cash Runway and Pipeline Catalysts Support DCF‑Backed Buy Rating and $13 Target
Premium
Ratings
Molecular Partners: Strong Cash Runway and Pipeline Catalysts Support DCF‑Backed Buy Rating and $13 Target
2M ago
MOLN
Undervalued Radioligand Leader: Molecular Partners’ Differentiated RadioDARPin Platform Underpins Buy Rating
Premium
Ratings
Undervalued Radioligand Leader: Molecular Partners’ Differentiated RadioDARPin Platform Underpins Buy Rating
2M ago
MOLN
Buy Recommendation on Molecular Partners: Advancing Radio-DARPin Platform, Strategic Isotope Collaboration, and Cash Runway Through 2028 Underpin Attractive Risk‑Reward
Premium
Ratings
Buy Recommendation on Molecular Partners: Advancing Radio-DARPin Platform, Strategic Isotope Collaboration, and Cash Runway Through 2028 Underpin Attractive Risk‑Reward
2M ago
MOLN
Buy Rating on Molecular Partners: Expanding Radiopharmaceutical Platform, Isotope Partnership, and Flexible DARPin Strategy Support Favorable Risk-Reward
Premium
Ratings
Buy Rating on Molecular Partners: Expanding Radiopharmaceutical Platform, Isotope Partnership, and Flexible DARPin Strategy Support Favorable Risk-Reward
3M ago
MOLN
Molecular Partners Advances DLL3 Radioligand Program With New Phase 1/2a Cancer Trial
Premium
Company Announcements
Molecular Partners Advances DLL3 Radioligand Program With New Phase 1/2a Cancer Trial
4M ago
MLLCF
More CH:MOLN News >

MOLN News on the Web

Molecular Partners announces presentation of preclinical data at AACR
TipRanks News
Bullish
Molecular Partners: Strong Cash Runway and Pipeline Catalysts Support DCF‑Backed Buy Rating and $13 Target
TipRanks News
Bullish
Undervalued Radioligand Leader: Molecular Partners’ Differentiated RadioDARPin Platform Underpins Buy Rating
TipRanks News
Bullish
Buy Recommendation on Molecular Partners: Advancing Radio-DARPin Platform, Strategic Isotope Collaboration, and Cash Runway Through 2028 Underpin Attractive Risk‑Reward
TipRanks News
Bullish
Molecular Partners (MOLN) Gets a Buy from Clear Street
TipRanks News
Bullish
Buy Rating on Molecular Partners: Expanding Radiopharmaceutical Platform, Isotope Partnership, and Flexible DARPin Strategy Support Favorable Risk-Reward
TipRanks News
Bullish
Molecular Partners enters Radio-DARPin therapeutics pact with Eckert & Ziegler
TipRanks News
Bullish
Molecular Partners AG conference call and Webcast Transcript
GuruFocus News
Neutral

News Score - Last 7 Days

Not enough data to generate a sentiment score
Media Buzz
This Week0 articles
Weekly Average1 articles
News Sentiment
Currently, no data available
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is CH:MOLN’s Media Buzz Sentiment?
Currently, no data Available
What is CH:MOLN’s weekly average amount of articles?
In an average week, 1 articles about CH:MOLN are published.
    What is CH:MOLN’s News Sentiment?
    Currently, no data Available
    Healthcare Stocks that are Trending in the News
    GOSSGossamer Bio
    RLAYRelay Therapeutics
    ROIVRoivant Sciences
    IMVTImmunovant
    PROKProKidney
    Showing the stocks with the most bullish news sentiment over the past week